Article

Eli Lilly and Nvidia are establishing an AI co-innovation lab in the San Francisco Bay Area, committing over $1 billion over five years to accelerate drug discovery and development. The lab will integrate Lilly's pharmaceutical expertise with Nvidia's AI capabilities, focusing on creating a continuous learning system that connects wet and dry labs for 24/7 AI-assisted experimentation.

Researchers will develop foundation models using the Nvidia BioNeMo platform to explore biological and chemical spaces, with the aim of shortening drug development timelines and enhancing clinical operations. Operations are expected to begin in early 2026, building on previous collaborations including an AI factory supercomputer designed for drug discovery.